Provisional Consent to the Distribution of New Medicines

Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

*Product:*	Candesartan Viatris
Active Ingredient:	Candesartan cilexetil 4mg
Dosage Form:	Tablet
New Zealand Sponsor:	Viatris Limited
Manufacturer:	Laboratorios Liconsa SA, Guadalajara, Spain
Note: This consent is given subject to the following condition: The medicine may only be marketed or distributed when no other candesartan medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet Pharmac supply obligations.
Note: This consent is valid for two years from the date of publication of this notice.

*Product:*	Candesartan Viatris
Active Ingredient:	Candesartan cilexetil 8mg
Dosage Form:	Tablet
New Zealand Sponsor:	Viatris Limited
Manufacturer:	Laboratorios Liconsa SA, Guadalajara, Spain
Note: This consent is given subject to the following condition: The medicine may only be marketed or distributed when no other candesartan medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet Pharmac supply obligations.
Note: This consent is valid for two years from the date of publication of this notice.

*Product:*	Candesartan Viatris
Active Ingredient:	Candesartan cilexetil 16mg
Dosage Form:	Tablet
New Zealand Sponsor:	Viatris Limited
Manufacturer:	Laboratorios Liconsa SA, Guadalajara, Spain
Note: This consent is given subject to the following condition: The medicine may only be marketed or distributed when no other candesartan medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet Pharmac supply obligations.
Note: This consent is valid for two years from the date of publication of this notice.

*Product:*	Candesartan Viatris
Active Ingredient:	Candesartan cilexetil 32mg
Dosage Form:	Tablet
New Zealand Sponsor:	Viatris Limited
Manufacturer:	Laboratorios Liconsa SA, Guadalajara, Spain
Note: This consent is given subject to the following condition: The medicine may only be marketed or distributed when no other candesartan medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet Pharmac supply obligations.
Note: This consent is valid for two years from the date of publication of this notice.

Dated this 27th day of March 2026.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

Tags

Notice Number

Schedule